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included in all studies. Furthermore, the model with prior imputation of the vari-
ance appeared to be more stable than two-stage model.
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SAMPLE SIZE AND ETHICAL CONSIDERATIONS IN RANDOMIZED CLUSTER
SAMPLING VERSUS INDIVIDUAL PATIENT RECRUITMENT FORMULAS IN
PROSPECTIVE OBSERVATIONAL STUDIES
Chiappinelli R, Stanley S, Criscola R, Wasser T
HealthCore, Wilmington, DE, USA
OBJECTIVES:Differences in computational sample size formulas indicate that ran-
domized cluster samples require more patients to demonstrate the same effect as
studies that use Individual Patient Recruitment (IPR) formulas. We compared the
differences in randomized cluster sampling and IPR formulas through a simulation
study by varying the cluster size and Intra-Cluster Correlation Coefficient (ICC) to
determine the magnitude of sample size differences. METHODS: The sample size
formula for cluster sampling included two terms: 1) estimate of cluster size, and 2)
estimate of ICC. Four Mean/Standard Deviation ratios were used reflecting the
effect size, three ICC values, and three cluster sizes. Sample size was calculated for
non-cluster and cluster formulas for 80% and 90% power. Sample size calculation
results between cluster and IPR formulas were compared. RESULTS: Differences
between cluster and IPR designs found that under sampling in IPR formulas vary
from 5-15% and are largest when effect sizes are smallest. The IPR samples were
smaller than cluster samples for the same effect size and power. Sample size using
the cluster formula was smallest when ICC was small (0.15), at 80 percent power
and cluster size of 5 patients per group. Cluster sample size was largest when ICC
was large (0.25), at 90 percent power and cluster size of 20. CONCLUSIONS: In the
research environment where prospective observational methods are used to
gather “real world” data, studies that are conducted using cluster sampling, but
powered with IPR formulas, are underpowered by as much as 15%. Ethical impli-
cations must be considered in prospective studies that require patient informed
consent if the study is underpowered. If the prospective study involves risk the
equipoise argument may be violated and place patients at risk (assuming there is a
study treatment regimen), as the study may not be conclusive because of low
power.
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NONPARAMETRIC REGRESSION ANALYSIS CONTROLS COST ANALYSIS IN
DATA WITH OUTLIERS
Eisenberg D, Wasser T
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OBJECTIVES: Cost analysis is often complicated to analyze because of skewed data
caused by outliers in the upper tail of the distribution. Some of these outlier ex-
penses are a result of extreme expenses before an observation period starts or
during an episode of illness. Theil regression is a non-parametric linear regression
method that provides accurate estimates of slope and intercept when outliers are
present by calculating values based on the median.METHODS: In a study intended
to measure the length of time it took for patient costs to return to normal pre-
episode costs after pneumonia, the Theil method was used and compared to Ordi-
nary Least Squares (OLS) results on the same data. The baseline cost was computed
as the mean cost for the six months prior to diagnosis, the study allowed for a three
month episode period and the OLS and Theil regression methods were computed
on the monthly costs for the six months after the episode. RESULTS: High cost
outliers during the three month episode led to elevated costs for the first post
episode period. This caused an underestimate of cost using the OLS method. Theil
regression correctly estimated the increased time to return to normal in 11 of the 21
variables tracked. These differences ranged from 15 to 370 days. OLS found ex-
tended time over Theil for 5 of 21 comparisons. These differences ranged from 2 to
26 days. Agreement between OLS and Theil was found for 5 of 21 comparisons.
CONCLUSIONS: Outliers in regression analysis frequently occur when the variable
of interest is cost. Theil regression offers considerable advantages over OLS regres-
sion when the outlier is in one of the tails of the distribution. The advantages
include more accurate results as well being able to use all the data without exclu-
sion of any data elements.
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SOCIOECONOMIC PATTERNS AMONG INTERNATIONAL IMMIGRANTS IN CHILE:
THE USE OF CLUSTERS
Cabieses B, Tunstall H, Pickett K, Espinoza M
University of York, York, Yorkshire, England
OBJECTIVES: International immigration to Chile has increased in the past decade.
Preliminary analysis found the immigrants were a very heterogeneous and polar-
ized group in their SES which makes it difficult to identify particular needs of
vulnerable subgroups within the total immigrant population. This analysis aims to
describe their SES patterns. METHODS: Cross-sectional Chilean survey (CASEN-
2006). From 268,873 participants, one percent were immigrants (n1.877). Cluster
analysis identifies subsets of a data set that contain similar points. Replacing these
subsets by their aggregate properties, it creates a compact representation of the
data set as a group of clusters. Hierarchical clustering is a step-wise process that
merges the two closest or furthest data points or groups of data points at each step.
Among the different types of hierarchical cluster analyses available, complete-
linkage method was chosen as it creates clusters from the most distant values of
the selected attributes (income, education and employment-status). Each SES-
cluster was analysed in its demographic (age/sex/marital-status), geographical (ur-
ban-rural/region), SES variables (income/education/occupation), material-stan-
dards (overcrowding/sanitary-conditions/housing-quality). Analysis in STATA
10.0. RESULTS: After conducting complete-linkage hierarchical cluster analysis,
three groups were identified: High-SES (n398), Medium-SES (n889), Low-SES
(n587). Key patterns are: High-SES: mean 35 years-old, 90% of working age, most
married, technical or university level, only 2.7% with ethnic background. Medium-
SES: mean 33 years-old, 60% technical education, mixed cluster. Low-SES: mean
25 years-old, 60% women, 8% ethnic background, up to high-school only, 2 poor-
est income quintiles. CONCLUSIONS: Immigrants in Chile are a very heteroge-
neous group, polarized by their SES. Hierarchical cluster analysis provided an ap-
propriate method to group immigrants according to their socio-economic
characteristics and, consequently, to provide clear patterns of SES vulnerability
within the total immigrant population. Immigrants living in the Low-SES cluster
are a vulnerable group that needs further attention in Chile.
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OBJECTIVES: Researchers have suggested that, propensity score (PS) adjustment
provides similar results as traditional regression analysis in observational studies.
This has been attributed to the inappropriate implementation of PS, like inclusion
of both PS and baseline covariates, and absence of covariate balance verification
after PS adjustment. The present study employed a multiple PS adjustment model
to evaluate the risk of falls/fractures in older adults using atypical antipsychotics,
performed a balance check of covariates after PS adjustment and compared the
results from multiple PS analysis with traditional regression model. METHODS:
The study used IMS LifeLink Health Plan Claims Database and included older adults
(aged  50 years) who initiated risperidone, olanzapine or quetiapine anytime
during July 1, 2000 to June 30, 2008. Patients were followed until hospitalization/
emergency room (ER) visit for falls/fractures, or end of the study period, whichever
occurred earlier. Cox proportional hazard regression model was used to evaluate
the relative risk of falls/fractures. The traditional model included over 80 baseline
covariates which were also used to calculate the PS. The PS model included the two
PS and their interaction terms. The covariate balance after PS adjustment was
checked using logistic regression. RESULTS: After PS adjustment, there was no
difference in any of the baseline covariates among the treatment groups. Both
traditional regression and PS analyses had similar findings. There was no statisti-
cally significant difference with use of risperidone (Traditional: Hazard Ratio, HR,
1.10, 95% CI, 0.86-1.39; PS: HR, 1.09, 0.86-1.38) or quetiapine (Traditional: HR, 1.10,
0.84-1.44; PS: HR, 1.12, 0.86-1.46) compared to olanzapine in the risk of falls/
fractures. CONCLUSIONS: The study findings suggest that, a PS adjustment model
with well-balanced covariates across treatment groups gives similar results as
traditional regression model.
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OBJECTIVES: Currently, the work of Schneeweiss, et al. (2009) for propensity score
adjustment is considered the standard approach for accounting for confounding in
large claims data sets and is endorsed by such bodies as the Observational Medical
Outcomes Partnership (OMOP) in the United States. The procedure appears to per-
form well and has many attractive features for the practitioner; however, exami-
nation of the selection of a set of potential effects for adjustment typically involves
the perusal of large tables of summary statistics. For large data sets with potentially
hundreds of covariates, this display does not afford the practitioner an easy, intu-
itive view of the relationships amongst the cofounders and with the desired out-
come under study. METHODS: Modification of simple categorical data visualiza-
tions suggested by Cleveland (1993), Keller and Keller (1993), Harris (1999), Friendly
(2001) and others were developed in common statistical software packages (e.g.
SAS). RESULTS: The individual and joint behavior of the contribution of various
confounders could be identified quickly and enhanced the user’s understanding of
their role in the procedure. CONCLUSIONS: In a setting with a large number of
confounders, the procedure suggested by Schneeweiss, et al. reduces the number
of confounders to a more manageable and practical level. Graphical techniques
help the practitioner achieve a better understanding of the role of these confound-
ers and the rationale for their inclusion in the adjustment procedure.
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A NEW APPROACH TO MODELING CANCER RECURRENCE AND FOLLOW-UP
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OBJECTIVES: The ability to model cancer recurrence could assist in the optimiza-
tion of surveillance strategies. However, capturing the dynamics of cancer recur-
rence in order to simulate follow-up surveillance after initial extirpative surgery
presents a significant methodological challenge. The difficulty of modeling recur-
rence patterns is that relevant experimental and observational data is collected in
the context of heterogeneous protocols for follow-up. Using the example of colo-
rectal cancer, we propose a method of controlling for choice of follow-up regimen
in order to infer the value of key natural history parameters. Once these values are
inferred, any hypothetical follow-up regimen can be superimposed upon the nat-
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ural history model to project clinical and/or economic outcomes. METHODS: The
subset of stage I-III colon cancer patients who will experience recurrence face a
constant rate rd of transition from undetectable to theoretically detectable recur-
rence during a given interval. These same patients face a constant rate ru of tran-
sition from resectable (i.e. potentially curable) to unresectable metastatic disease
with a minimum interval xdu between the point of detectability and the point of
unresectability. A third constant rate parameter rs will determine when, on aver-
age, individuals develop recurrence-related symptoms prompting them to seek
medical advice before the next scheduled evaluation. The mean point of symptom
development will follow the point at which a recurrence becomes detectable by a
span of at least xds. However, a normally distributed error term Eds will mean that,
for a given simulated patient, symptoms may initiate before or after the patient
reaches unresectability.RESULTS:A best-fitting set of these natural history param-
eters can be selected by calibrating to targets of time-to-detection of recurrence,
time-to-death, and proportion of patients who present with recurrence-related
symptoms prior to scheduled assessments. CONCLUSIONS: The data sources for
these targets can be existing experimental, observational, or registry data where
follow-up schedule and compliance levels are known.
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DIFFERENTIAL DISCOUNTING: QUESTIONING THE ASSUMPTION OF
HEALTHCARE RESOURCE FUNGIBILITY OVER TIME
O’Mahony J
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OBJECTIVES: Recent work on differential discounting of cost and health effects has
reached a degree of consensus in a previously strongly divided debate. Put simply,
it holds that the discount rate applied to health effects should equal the discount
rate for costs, less the growth rate of either the cost-effectiveness threshold or the
consumption value of health, depending on the objectives of the health system.
Assuming positive growth in the threshold or the value of health, this implies the
cost-effectiveness of preventative interventions improves relative to the situation
under equal discounting. METHODS: We show how recent analyses of differential
discounting implicitly assume healthcare funds to be completely fungible over
time. This assumption is difficult to justify in the context of publically funded
healthcare systems that exhaust budgets annually. Assuming funds are not fungi-
ble results in alternative differential discount rates: in this case, the discount rate
on costs should be adjusted upwards by either the growth rate of the threshold or
the consumption value of health. RESULTS: Under these discount rates, interven-
tions that impose costs in future periods become more cost-effective relative to the
situation under equal discounting, rather than those which yield health gains in
the future. Indeed, the cost-effectiveness of preventative interventions that reduce
future healthcare costs will deteriorate under such alternative differential dis-
counting. Consequently, interventions’ cost-effectiveness may differ greatly be-
tween the two differential discounting schemes. CONCLUSION: Cost-effectiveness
estimates can be highly sensitive to discounting; therefore the theory underpin-
ning discount rates needs to be robust. This analysis shows that the current un-
derstanding of differential discounting needs to be re-examined. CEA authorities in
countries currently employing differential discounting such as Belgium and The
Netherlands and those contemplating it such as England and Wales should con-
sider these issues carefully.
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REVISITING HPV VACCINATION: WHY EXISTING CEAS UNDERESTIMATE THE
VACCINE’S COST-EFFECTIVENESS AND INCORRECTLY ESTIMATE ITS
THRESHOLD PRICE
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OBJECTIVES: Existing cost-effectiveness analyses (CEAs) of Human Papillomavirus
(HPV) vaccination assume cervical screening remains unchanged. However, cur-
rent screening intensities are unlikely to be cost-effective due to the likely reduc-
tion in disease incidence in vaccinated women. Therefore, reductions in screening
intensity are probable. The cost-effectiveness attributable to vaccination varies
with screening intensity. The assumption of unaltered screening leads to an un-
derestimation of vaccine cost-effectiveness relative to when screening intensity is
reduced. Furthermore, failure to consider other screening intensities yields an in-
complete efficient frontier in the cost-effectiveness plane. This can lead to an
incorrect estimate of the price at which vaccination becomes marginally cost-
effective for a given cost-effectiveness threshold. METHODS: We review cost-ef-
fectiveness estimates for a wide range of screening only and vaccination plus
screening strategies from a model used to estimate vaccine cost-effectiveness in
the The Netherlands. We indicate what comparison was used to estimate vaccine
cost-effectiveness in previous studies, show what comparisons would be more
appropriate and explain how these differ. RESULTS: We then show why the cost-
effectiveness of adding vaccination to a given screening strategy is not the appro-
priate basis to determine if the vaccine is cost-effective or the threshold price.
Rather, both should be determined by the ICER between the most costly efficient
screening only strategy and the least costly vaccination plus screening strategy,
even where this least costly vaccination plus screening strategy is not the optimal
strategy for a given threshold. CONCLUSIONS: CEAs of HPV vaccination may no
longer be policy or research priorities following widespread reimbursement and
precipitous price reductions. However, the methodological issues raised here are
pertinent to both any future CEA of an enhanced vaccine with protection against
more HPV types and more generally to cases in which the cost-effectiveness of
complementary interventions are not independent.
PRM58
METHODOLOGICAL REVIEWS OF ECONOMIC EVALUATIONS IN HEALTH CARE:
ARE THEY USEFUL?
Hutter MF, Antonanzas F
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INTRODUCTION AND OBJECTIVES: The increasing amount of economic evalua-
tions in health technologies published during the last decades have generated the
concern about their methodological features. The aim of this study is, firstly, to
explore methodological reviews and to detect their main research topics and, sec-
ondly, to appraise their usefulness for economic evaluation practice. METHODS:
We performed systematic searches in electronic databases (Scopus, Medline and
Pubmed) of methodological reviews published in English, period 1990- 2010. We
selected those articles whose main purpose was to review and assess the applied
methodology. Then we classified data according to study objectives, period of the
review, number of reviewed studies, methodological items assessed and their
main conclusions. Additionally, we checked how generalizability issues were con-
sidered in the reviews. RESULTS: A total of 58 methodological reviews were iden-
tified, 42 were published during the period 1990 - 2001 and 16 during 2002-10. Items
most frequently assessed (by 70% of the reviews) were: perspective, uncertainty
and discounting. The type of intervention and disease, funding sources, country in
which the evaluation took place, type of journal and author’s characteristics were
also described in the literature. Generalizability issues were only checked in 14
studies, mainly by those published after 2000. CONCLUSIONS: there is an increas-
ing activity of reviewing economic evaluation studies aiming to analyse the appli-
cation of methodological principles and to offer summaries of papers classified by
either diseases or health technologies. These reviews are useful to detect literature
trends, targets of the studies and possible deficiencies in the implementation of the
methods to specific health interventions.
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RATIO FROM A FAMILY OF REGRESSIONS ON NET MONETARY BENEFIT
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OBJECTIVES: To demonstrate a novel way of deriving the incremental cost-effec-
tiveness ratio (ICER) and associated 95% confidence interval (CI) from the cost-
effectiveness acceptability curve (CEAC) generated from a family of regressions on
net monetary benefit (NMB). METHODS: Definitions and mathematical properties
of the ICER, NMB, and CEAC are explored to construct a technique for deriving 95%
CIs around the ICER estimated from the CEAC. RESULTS: CEA uses the ICER, a
measure with statistical issues that preclude easy derivation of confidence inter-
vals. NMB is defined for any willingness-to-pay (WTP) value as: NMB  (effective-
ness X WTP) – cost. Because NMB is statistically well-behaved, regression analysis
can estimate incremental net monetary benefit (INMB) as the parameter estimate
associated with treatment. INMB  (delta effectiveness X WTP) – delta cost. The
CEAC is generated from a family of these regressions where the unique members of
the family are identified by unique levels of WTP used to calculate NMB. The ICER
is the point on the CEAC where the probability of being cost-effective is 50%, be-
cause at that point INMB is zero and WTP equals delta cost/delta effectiveness; i.e.,
the ICER. That point on the CEAC can be identified numerically by simultaneously
solving the two equations for INMB from the two regressions that flank estimated
INMB of zero. Knowing estimated INMB and the WTP we have two equations and
two unknowns, and we solve for delta effectiveness and delta cost. We use a similar
procedure on the 95% confidence intervals for two estimated INMBs to find the 95%
CI for the ICER. CONCLUSIONS: In the case where we estimate the ICER from a
family of regressions on NMB to construct the CEAC we can also find the 95% CI of
the ICER.
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OBJECTIVES: In the absence of increasing budgets, new therapies and resource
constraints have necessitated value trade-offs across tumor types and products.
Traditional metrics such as median overall survival (OS) may not fully demonstrate
the value of individual products in these comparisons. To highlight this, we as-
sessed the value of different innovative cancer drugs relative to their clinical trial
comparator using a variety of OS metrics. METHODS: We selected novel oncology
products used in the treatment of metastatic disease with documented overall
survival benefit over comparator at the time of launch. The selected products were:
bevacizumab (colorectal cancer, non squamous non-small cell lung cancer),
sunitinib (renal cell carcinoma), sorafenib (hepatocellular carcinoma), lenalido-
mide (multiple myeloma), ipilimumab (melanoma), trastuzumab (breast cancer).
Key survival metrics including median OS, mean OS, and landmark survival rates
from each analogue’s pivotal trials were used to assess the relative value of each
analogue. RESULTS: The relative value for each analogue differs depending on the
survival metric used, suggesting that median OS does not fully capture the value of
oncology agents. For example, lenalidomide’s relative value is the highest in terms
of median OS improvement; however its relative value is diminished when looking
at mean OS. Ipilimumab, conversely, shows the highest value in terms of mean OS
(attributing benefit to a proportion of patients achieving prolonged survival bene-
fit). Furthermore, sorafenib (HCC) and ipilimumab (melanoma) demonstrate the
highest relative value when evaluating 1 year survival improvement.
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